Research

The Department of Neurology participates in many clinical research studies. Our most recent clinical trials involve ALS, Parkinson's Disease, Epilepsy, Multiple Sclerosis and Cerebrovascular Disease/Stroke.

Current Research Trials:

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Episodic Cluster Headache (Protocol TV48125-CNS-30056) PI: David B. Watson MD

Teva Branded Pharmaceutical Products R & D

CRO: NCGS

1611350588

Open to Enrollment

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Chronic Cluster Headache (Protocol TV48125-CNS-30057) PI: David B. Watson MD

Teva Branded Pharmaceutical Products R & D

CRO: NCGS

1611350853

Open to Enrollment

A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache (Protocol TV48125-CNS-30058) PI: David B. Watson MD

Teva Branded Pharmaceutical Products R & D

CRO: NCGS

1611351260

Open to Enrollment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine (Protocol   TV48125-CNS-30049) PI: David B. Watson MD

Teva Branded Pharmaceutical Products R & D

CRO: NCGS

1604085070

Closed to Enrollment

Sponsor in process of closing out sites

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine (Protocol TV48125-CNS-30050) PI: David B. Watson MD

Teva Branded Pharmaceutical Products R & D

CRO: NCGS

1604086024

Closed to Enrollment

Sponsor in process of closing out sites

A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine (Protocol TV48125-CNS-30051) PI: David B. Watson MD

Teva Branded Pharmaceutical Products R & D

CRO: NCGS

1604086056

Closed to Enrollment

Sponsor in process of closing out sites

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Attack Study To Evaluate The Efficacy, Safety, and Tolerability of Oral Ubrogepant In The Acute Treatment of Migraine (Protocol UBR-MD-02) PI: David B. Watson MD

Allergan Sales, LLC

1608249960

Open to Enrollment

A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant In The Acute Treatment of Migraine With Or Without Aura (Protocol UBR-MD-04) PI: David B. Watson MD

Allergan Sales, LLC

1608250247

Open to Enrollment

Title

Sponsor

IRB KC Number

Status

A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)   (Protocol CY 4031) PI: Shumaila Sultan MD

Cytokinetics, Inc.

CRO: Parexel

1505698254/1606162563

Closed to Enrollment

Patients in active long-term follow-up

A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY4031) (Protocol CY 4033) PI: Shumaila Sultan MD

Cytokinetics, Inc.

CRO: Parexel

1609296113

Open to Enrollment

A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK-2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS) (Protocol CY 5022) PI: Shumaila Sultan MD

Cytokinetics, Inc.

CRO: Parexel

IRB Pending/Not Submitted

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache (Protocol I5Q-MC-CGAL) PI: David B. Watson MD

Eli Lilly and Company

CRO: Quintiles

1503605634

Open to Enrollment

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache (Protocol I5Q-MC-CGAM) PI: David B. Watson MD

Eli Lilly and Company

CRO: Quintiles

1505677968

Open to Enrollment

A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache (Protocol  I5Q-MC-CGAR) PI: David B. Watson MD

Eli Lilly and Company

CRO: Quintiles

IRB Pending/Not Submitted

Awaiting sponsor approval of consents

Controlled Trial of 3, 4 Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS) PI: Shumaila Sultan MD

Sponsor-Investigator (WVU holds IND)

Jacobus Pharmaceuticals

1402212067

Open to Enrollment

Patients in Long-term follow-up

A Phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-naïve patients with late onset Pompe disease (Protocol EFC14028) PI: Cheryl Smith MD, PhD

Sanofi-Genzyme

IRB Pending/Not Submitted

A Pilot Study of Muscle Ultrasound Measures As Biomarkers of Upper Motor Neuron Function PI: Shumaila Sultan MD

Investigator-initiated

1703516653

Open to Enrollment

Neuroelectrical Stimulation in Guillian Barre Syndrome PI: Cheryl Smith MD, PhD

Investigator-initiated

1703497861

IRB Pending

If you have any questions regarding the above listed research please contact:

Patricia Altemus, MS,
Neurology Research Coordinator
Phone: 304-598-4000 ext: 75656